Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Pubmed ID: 22085343

Journal: The New England journal of medicine

Publication Date: Dec. 15, 2011

MeSH Terms: Humans, Male, Female, Aged, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Middle Aged, Proportional Hazards Models, Kaplan-Meier Estimate, Medication Adherence, Cholesterol, HDL, Drug Therapy, Combination, Atherosclerosis, Triglycerides, Cholesterol, LDL, Hypolipidemic Agents, Brain Ischemia, Treatment Failure, Simvastatin, Muscular Diseases, Niacin

Authors: Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Boden WE, Probstfield JL, Chaitman BR, Weintraub W, Desvignes-Nickens P, Teo K, Anderson T, McBride R, Koprowicz K, Boden WE, Probstfield JL, McBride R, Anderson T, Kashyap M, Chaitman BR, Marcovina S, Weintraub W, Zhao XQ, Teo K, Desvignes-Nickens P, Fleg JL, McGovern ME, Stolzenbach JC, Padley RJ, Samaha F, Anderson T, Kashyap M, Boden WE, Marcovina S, McBride R, Probstfield JL, Weintraub W, Goldberg R, Guyton J, Fleg J, Desvignes-Nickens P, McGovern M, Chaitman BR, Anderson DC, Bach RG, Cruz-Flores S, Gosselin G, Nash SD, Sila CA, Desvignes-Nickens P, Fleg J, Yang S, Wittes J, Arnett D, LaRosa J, Orchard T, Watson KE, Meslin EM, Hsia J, Probstfield JL, McBride R, Kaiser J, Seymour K, Claire S, Ricker B, Wallum C, Nelson J, Yi H, Peck S, Ruha C, Jarvis K, Lacroix A, Mitchell L, Mitchell R, Collins P, Putnam R, Trotter K, Nasco E, Shemanski LR, Koprowicz K, Ng G, Saunders K, Ng G, McConney M, Grant S, Liu T, Chaitman B, Bertram T, Stocke K, Marcovina S, Harting J, Herrington D, Wayne V, Doomy L, Zhao XQ, O'Brien K, Williams S, Geohas C, Prasad R, Laborin A, Talbot P, Tremblay M, Talbot MC, Auger P, Bilodeau N, Dumont F, Cote M, Wickemeyer W, VanEffen S, St-Hilaire R, Morissette A, Gilbert N, Guyton J, Khan S, Ramadanovic K, Kashyap M, St Vrestil N, Fallye O, Anderson T, Madden B, Crouse J, Davis D, Terry G, Kouba E, Sperl-Hillen J, Cook S, Chadha C, Gallo R, Brousseau M, Bujold S, Ratliff M, Elliott R, Wagoner K, Samaha F, Zeng L, Wightman H, Slipp S, Goldberg R, Sabogal D, Craig W, Heath J, Miller B, Pandey A, Irvine B, Wang C, Ross B, Henegar L, Simpson A, Bailes L, McKenzie R, McGuinn P, Humphrey K, Walton A, Lonn E, Miller B, Kostuk W, Bone C, Fung A, Fox R, Gosselin G, David M, Harvey N, Sussex B, Luther AM, Kopecky S, Woltman C, Shelstad D, Janosik D, Havlin K, Newgent J, Nawaz S, Dewar C, Lehmann K, LaGuire J, Demons J, Wittmer T, Bilazarian S, Roach K, Lader E, Meyer M, Miro M, Plant R, Budzon S, Nash S, Moore J, Miller M, Roberts A, Wysham C, Yedinak S, Weeks D, Leiter L, Berndl L, Burnett M, Elam M, Peeples S, Turner J, Hess A, McPhearson C, Murdock D, Peksa M, Robinson J, Merideth N, Furlong DC, Sadler L, Desmit M, Zaletel T, Karalis D, Budzinski S, Galardi S, Murphy E, Avalos K, Krall T, Katz L, Richardson E, Nieves A, Gagne C, Sills J, Title L, Cossett J, Francis M, Knopp R, Paramsothy P, Dowdy A, Twaddell B, Fagan T, Deckert J, Montante L, Claire D, Rose P, Zoble R, Fernandez I, Carstens J, Taylor J, Ma P, Louch D, Kielson L, Teufel E, Glasgow B, Peterson K, Dodds E, Roberts B, Leary P, Jones P, Tanksley D, Grunberger G, Douglas D, Force R, Murdock N, Lusk S, Gamble K, Norris R, Boyle M, Yoon J, Kwiterovich P, Byrne K, Rashid HU, Meadows S, Zieve F, Kimmel M, Bittner V, Fitz-Gerald M, Douglas G, Collings E, Chaudhuri A, Martin L, Gamel C, Simmons D, Dishongh K, Ayenew W, Lascewski D, Goldenberg E, Laucirica J, Woo V, Mandock C, Berard L, Reeves R, Williams B, Frew S, Huynh M, Grudzinski S, Baker C, Muhlestein B, Jacketta-Dunyon C, Bredlau C, Heineman A, Roth E, Piccola J, Klinke P, Lounsbury N, Della Siega A, Kostis J, Cosgrove N, Colletti P, Contreras A, Hoffman A, Rangel M, Felicetta J, Cook S, Dunbar R, Williams M, Eisenberg D, Rolph B, Donovan D, Lopez-Jimenez C, Russell M, Davis D, Lipke S, Gelernt M, Vogt T, DeYoung P, Watt M, Brass N, Kvill L, Kwong D, Edwards J, Tam K, Parker S, Schubart U, Gutierrez C, Cheatham W, Wells D

Cite As: AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 Dec 15;365(24):2255-67. Epub 2011 Nov 15.

Studies:

Abstract

BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS: We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS: A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).